tools, like the one described here, to help them control these important nosocomial pathogens. resistant Staphylococcus aureus (MSSA and MRSA) are pathogens of growing concern to clinicians. 1 In the past 2 decades, an increase in MRSA colonization has been observed in the United States. 1, 2 This is especially true of community-associated MRSA, which is increasing in the general population and is known to cause severe skin and pulmonary infections in individuals without traditional risk factors. 1, 3 In ophthalmology, manifestations of MSSA and MRSA infection include preseptal cellulitis, dacryocystitis, blepharoconjunctivitis, orbital cellulitis, blebitis, keratitis/ corneal ulcer, and endophthalmitis. 4, 5 Among these infections, community-associated MRSA has been reported as 1 of the emerging causes involved. 6, 7 Thus, as the prevalence of community-associated MRSA increases in the general population, infection-control measures, which are critical to the inpatient environment, could be adapted for outpatient settings to evaluate for S. aureus surface contamination and to evaluate and improve the effectiveness of clinic cleaning and disinfection practices.
Studies in hospital settings have shown that commonlytouched surfaces, such as computer keyboards 8 and bloodpressure cuffs, 9 among others, could be potential sources of S. aureus colonization and infection in patients. MSSA and MRSA can survive for days to months on inanimate surfaces. [10] [11] [12] In light of this, the widespread presence of hospital-associated MRSA and the increasing prevalence of community-associated MRSA, one must question whether surfaces in the outpatient setting also pose transmission risks for patients and employees.
To identify effectively the surfaces most commonly contaminated with pathogens like MSSA and MRSA and allow for molecular typing, an economic, standardized sampling protocol has been developed. 13, 14 This tool is valuable to evaluate the effectiveness of cleaning and disinfection practices and could contribute to a surveillance program with the goal of minimizing potential patient and personnel exposure to MSSA and MRSA strains as well as other nosocomial pathogens.
The purpose of this study was to use a standardized sampling protocol to screen ophthalmic clinic equipment and commonly touched surfaces for MSSA and MRSA; to identify the most commonly contaminated clinic surfaces; and to further phenotype and genotype such isolates. This study could provide valuable information for the development of surveillance programs that evaluate and improve future cleaning and disinfection protocols for outpatient clinical settings.
METHODS
EXPERIMENTAL DESIGN: This study was carried out in a large academic ophthalmology setting. A standardized method (described below) was used to sample 12 randomly selected examination rooms and shared imaging rooms in 2 ophthalmology clinic buildings belonging to the same system (1 freestanding outpatient clinic, clinic 1; and 1 hospital-adjoining clinic, clinic 2). To be able to cover as many locations as possible from the clinic, the same surface in 3 different examination rooms was sampled as a pool. For example, all tonometer tips from each set of 3 rooms were pooled into 1 sample. Each group of rooms was denoted group A, group B, etc. (Table 1) . Items sampled in each examination room included patient-contact surfaces, such as slit-lamp, headrests and chinrests and tonometer tips; employee-contact surfaces such as computer keyboards and hand-sanitizer dispensers; and general contact surfaces such as doorknobs. Excluding shared imaging areas, 12 examination rooms of 43 (28%) were sampled (Table 1) .
Shared imaging equipment and imaging room contact surfaces (doorknobs, keyboards, head/chinrests, A-and B-scan ultrasound probes) in both clinic buildings were also tested. In these areas, a total of 3 surfaces were not always available, so the number of samples included in each pool can be found in Table 1 . The sampled surfaces were identical in all subsequent samplings. Overall, a total of 28 pooled samples from both examination and imaging rooms were collected on each date, representing a total of 76 individual surfaces.
Sampling was performed quarterly for 1 year. For the initial survey, rooms were selected randomly, and the same cadre of rooms and surfaces was screened for each subsequent survey. In each case, sampling was conducted at the end of the workday, after the clinics had closed and before daily cleaning and disinfection procedures were performed by the housekeeping staff.
SAMPLE COLLECTION AND PROCESSING: Samples were systematically collected from commonly touched surfaces by either cotton-tipped swabs (for smaller surface areas) that were premoistened to enhance sensitivity 15 or by 10.4 3 8.0 inch (26.5 3 20.3 cm) dry electrostatic cloths (for larger surface areas). The electrostatic nature of the cloth enhances sensitivity of bacterial collection. 16 For doorknob samples, the area immediately surrounding the doorknob was also sampled, up to about 1 foot from the knob and on both sides of the door. Slit-lamp headrests and chinrests were sampled at both forehead points and chin points of contact. Sampling was conducted by trained personnel wearing clean clothing covers and gloves, which were changed between each sample collected. After each sample was collected, swabs were immediately placed in tubes containing sterile trypticase soy broth (TSB, BD BBL; Becton, Dickinson) with 2.5% NaCl, while cloths were placed in sterile empty transportation bags (Nasco Whirl-Pak; Fort Atkinson, WI, USA). All samples were taken immediately to the Diagnostic and Research Laboratory on Infectious Diseases and processed as previously described, with a few modifications. [13] [14] [15] Briefly, a pre-enriched medium (TSB with 2.5% NaCl) was added to each bag containing the dry cloths. Tubes with swabs as well as bags with cloths were incubated for 24 hours at 35 8 C, then grown on mannitol salt agar plates (BD BBL mannitol salt agar; Becton, Dickinson). Finally, 3 colonies with typical mannitol reactions were plated on 5% sheep blood plates (Remel; blood agar [trypticase soy agar, TSA, with 5% sheep blood]; Thermo Fisher Scientific, Lenexa, KS) to be further characterized. Typical morphologic colonies of S. aureus were confirmed by standard biological testing. The MRSA phenotype was confirmed by growth on oxacillin screen agar plates (OSA, BD BBL Becton-Dickinson) containing 6 mg/mL of oxacillin supplemented with NaCl following the Clinical Laboratory Standards Institute protocols. 17 PHENOTYPING AND GENOTYPING: Antimicrobial resistance of all S. aureus isolates was established by the Kirby Bauer method using an array of 15 antibiotics (ampicillin 10 mg, amoxicillin/clavulanate 30 mg, oxacillin 1 mg, cephalothin 30 mg, cefpodoxime 10 mg, ciprofloxacin 2 mg, erythromycin 15 mg, gentamicin 1 mg, amikacin 30 mg, clindamycin 2 mg, tetracycline 30 mg, doxycycline 30 mg, trimethoprim/sulfamethoxazole 25 mg, moxifloxacin 5 mg, and chloramphenicol 30 mg). Resistance to vancomycin was tested using vancomycin screen agar plates (BD BBL Vancomycin Screen Agar; Becton-Dickinson). For quality control purposes, the following strains were included: S. aureus (ATCC 43300); S. aureus (ATCC 29213); S. aureus (ATCC 25923); Enterococcus faecalis (ATCC 23212); Escherichia coli (ATCC 25922); and Pseudomonas aeruginosa (ATCC 27853).
Molecular characterization of S. aureus isolates was performed as previously described.
14 Briefly, pulsed-field gel electrophoresis was performed in a CHEF mapper system (Bio-Rad Laboratories, Nazareth, Belgium) to separated restriction fragments obtained from the digestion of chromosomal DNA with SmaI. Salmonella serotype Branderup strain H9812 was digested with XbaI and used as a molecular size marker. Relatedness between isolates was evaluated by dendrogram analysis of the resulting pulsed-field gel electrophoresis band patterns using commercial software (BioNumerics, v 6.6, Applied Maths, Ghent, Belgium). The dendrogram was generated by using the Dice coefficient and the unweighted pair group method with arithmetic averages, with a 1% band position tolerance. Based on percentage of similarity, band patterns were classified as clones or the same pulsotype (> _98%) and grouped in clusters (> _80%). To establish US types, all S. aureus isolates obtained in this study were compared against a Centers for Disease Control and Prevention (CDC) database containing 100 S. aureus strains with the most typical band patterns for each US type, using > _80% similarity as the cutoff point. For MRSA isolates, mecA gene confirmation and SCCmec typing was performed as well.
RESULTS

DURING THE YEAR, S. AUREUS WAS DETECTED ON 30 OF 112
(28% overall; prevalence 14%-39% over time) total samples. Of these, 25 were MSSA, and 5 were MRSA (Table 2) . MSSA prevalence ranged from 14% to 29%, and MRSA ranged from 0 to 11%. One surface tested positive for both MRSA and MSSA simultaneously.
Three surfaces also tested positive for either methicillinsusceptible or methicillin-resistant (2 susceptible, 1 resistant) Staphylococcus pseudintermedius, an opportunistic pathogen commonly found in dogs which rarely, if ever, plays a pathogenic role in humans. 18, 19 MSSA was found in the clinic environment on all 4 sampling dates, while MRSA was found on 3 of 4 sampling dates ( Table 1, Table 2 ). In November 2010, MSSApositive samples included computer keyboards and doorknobs from both clinics' shared imaging areas, as well as the doorknobs of 1 examination room pool. In addition, a single MRSA-positive sample came from slit-lamp headrests and chinrests in group C (Table 1 ; Isolate 012a in Figure) . The same surfaces in each room were sampled in pools of 3 with either a premoistened cotton-tipped swab (Swab) or an electrostatic cloth (Cloth). Some imaging-area samples had fewer surfaces from which to sample; number of surfaces included in the pool is denoted in column 2.
In February 2011, 3 months later, the same headrest and chinrest pool from group C was again MRSA-positive (Isolate 040a, Figure) . Although these isolates were from the same cluster, they were not the same clone. MRSA was also found on 2 other surfaces: imaging area headrests and chinrests and computer keyboards (Isolates 031a and 053a, Figure) . MSSA was found on several other surfaces, but the same clone was not found on more than 1 surface on that date.
In May 2011, MRSA was detected on slit-lamp headrests and chinrests in group D (Isolate 073b, Figure) . In addition, MSSA was found on the doorknobs, hand sanitizer dispensers, and computer keyboards of group D; all these isolates (074a, 075a, 076a) were the same pulsotype, suggesting a common source and possible cross-contamination.
At the final sampling in August 2011, no surfaces were MRSA-positive. However, the same MSSA clone was found on the slit-lamp headrests and chinrests of group A and on the hand sanitizer dispensers of group B. All other MSSA isolates from this date were not clonally related.
Although many surfaces tested positive at some point for MSSA or MRSA (Table 3) , no surfaces directly contacting the eye (tonometer tips or A-and B-scan ultrasound probes) yielded a positive result at any point. The most commonly contaminated surfaces were doorknobs, with 11 of 24 (46%), and slit-lamp headrests and chinrests, with 10 of 24 (42%) sampled surfaces testing positive either for MSSA or MRSA over the course of the year. The third most contaminated surfaces were computer keyboards used only by clinic personnel, with 6 of 24 (25%) samples returning positive. MRSA, specifically, was most likely to be found on slit-lamp headrests and chinrests (4/24; 17%) and on computer keyboards (1 of 24; 4%).
Some of the 30 S. aureus-positive surfaces contained more than 1 unique isolate; thus, there was a total of 32 S. aureus isolates that were molecularly characterized. Of the 27 MSSA isolates, there were 20 individual pulsotypes, and of the 5 MRSA isolates, there were 4 unique pulsotypes.
Of the MSSA isolates, on 2 occasions the same clone was found in 2 separate examination room pools on the same sampling date (Figure, isolates 086 c, 093 a; isolates 061  a, 064 a) . Another pulsotype was found in different examination rooms on different dates ( Figure, isolates 010 a, 036  a) . Finally, a third common pulsotype was found on multiple surfaces in a single pool of examination rooms on a single sampling date ( Figure, isolates 074 a, 075 a, 076 b) . No single MSSA or MRSA clone was found on the same surface on consecutive dates.
When considering the MRSA isolates, 3 of 5 (60%) were community-associated MRSA (SCCmec IV, USA300), and 2 of 5 (40%) were hospital-associated MRSA (SCCmec II, USA100). [20] [21] [22] [23] Of the 3 community-associated MRSA isolates, 2 were the same clone ( Figure, isolates 031 a, 073 b) ; these were collected from 2 separate clinic buildings on 2 separate sampling dates. The 2 hospital-associated MRSA samples were different clones.
USA types for all samples (MSSA and MRSA) included USA100, USA200, USA300, USA500, USA600, USA700, and USA800. Of 30 S. aureus-positive samples, 9 did not match with > _80% similarity when compared against the CDC database; thus they were classified as not typeable. As previously mentioned, all hospitalassociated MRSA were USA100 clones, and all community-associated MRSA were USA300 clones.
Regarding antibiotic-resistant profiles, of the 27 MSSA isolates, 3 were pan-susceptible and 13 were resistant only to ampicillin. An additional 2 were resistant to ampicillin and erythromycin alone, and a final cluster of 6 isolates was resistant to ampicillin, erythromycin and clindamycin (though the clindamycin resistance was inducible).
Antibiotic resistance to multiple drugs was prevalent in the MRSA-positive samples. Of 5 (80%) MRSA isolates, 4 were resistant to 3 or more classes of antibiotics (Table 4) . The 2 hospital-acquired strains were resistant to betalactams, fluoroquinolones, macrolides, and lincosamides. A single community-acquired strain was resistant to betalactams only; the other 2 added macrolides and either fluoroquinolones or lincosamides to their resistance profiles.
DISCUSSION
IT REMAINS UNKNOWN WHETHER THE PRESENCE OF
S. aureus on eye clinic instruments and surfaces presents a transmission or infection risk for patients. Our data confirm the presence of MSSA/MRSA on ophthalmology clinic surfaces that are both patient-and employeecontact items, the most common being doorknobs, slitlamp headrests and chinrests and computer keyboards.
On all sampled surfaces over 1 year, MSSA was always present (14%-29%), and MRSA contaminated up to 1 in 10 surfaces (0-11%). Of the MSSA/MRSA-positive surfaces, none contact the eye directly (ultrasound probes and tonometer tips). Although this result could be related to the fact that these items are smaller and have limited surface area from which to sample, it could also mean that these surfaces are simply more clean than the others sampled because of more diligent cleaning and disinfection practices (typically cleaned with alcohol swab between each patient). The fact that these surfaces did not carry S. aureus is encouraging, and appears to suggest that frequent disinfection can eliminate detectable S. aureus from equipment surfaces.
The majority of MRSA isolates found in our study were collected from slit-lamp headrests and chinrests. In addition, after doorknobs, this was the second most commonly contaminated surface by S. aureus. Our results suggest that these surfaces may be hotspots for this type of pathogen, and cleaning protocols may need to be tailored to impact its presence.
Molecular analysis of all 27 MSSA isolates demonstrated 20 unique pulsotypes-a great amount of diversity. Likewise, of the 5 MRSA isolates, 4 unique pulsotypes were demonstrated. This, coupled with the fact that we found the same clone in different clinic buildings on different sampling dates, would suggest a constant introduction of new S. aureus clones into the clinic. Additionally, no single pulsotype remained prevalent in the clinic over time; ie, surfaces did not seem to have a single endemic strain of S. aureus. This suggests that current cleaning protocols are effective in preventing pathogens from spreading or becoming endemic in the outpatient environment.
As previously mentioned, several MSSA clones were detected on multiple surfaces on the same sampling date ( Figure, isolates 074 a, 075 a, 076 b; isolates 086 c, 093 a; isolates 061 a, 064 a), or the same clone was detected on separate sampling dates ( Figure, isolates 010 a, 036 a) . The former situation could suggest cross-contamination of surfaces by clinic staff and might be impacted by more diligent hand sanitization. The latter situation suggests a constant reintroduction of clones to the clinic environment, making continued vigilance with disinfection protocols essential.
Regarding antibiotic-resistance profiles, of the 27 MSSA isolates, most were resistant only to ampicillin or were pan-susceptible, as expected. However, several isolates displayed inducible clindamycin resistance, which may be particularly relevant to clinicians because it demonstrates that though these samples show in vitro susceptibility to the drug, they nevertheless demonstrated higher likelihood of in vivo resistance. It is beneficial to know the policies of one's microbiology laboratory and whether inducible clindamycin resistance testing is part of routine testing.
Quinolone resistance in samples was also noted: 1 MSSA pulsotype from the August sampling date (found on slitlamp headrests and chinrests and on hand sanitizer dispensers of 2 separate pools) demonstrated resistance to ciprofloxacin. Both hospital-associated MRSA strains showed resistance to this drug as well as to moxifloxacin; however, the communityassociated MRSA strains did not display quinoloneresistance. This is particularly relevant to clinicians, given that quinolone antibiotics are so commonly used in ophthalmology. 24 Quinolone resistance, while less common than resistance to other medications, has been shown to be prevalent among S. aureus and epidermidis species. [25] [26] [27] Furthermore, Hesje and associates 6 reported that the proportion of community-associated MRSA strains demonstrating resistance to 3 or more classes of antibiotics is considerable (62.5% in their study), and this fact should also be considered when determining empiric treatment for ocular infections. Rutar and associates 28 submit that community-associated MRSA is no longer specific to highrisk populations, but is rather a much more widespread and virulent organism.
As recently suggested by Hsaio and associates, 29 the portion of ocular MRSA infections that are communityassociated is increasing, and community-associated MRSA may become more important in the ophthalmology outpatient environment. Despite small sampling numbers, our study may support this conclusion. In addition, the degree of antibiotic resistance in the studies by Hsaio and associates 29 and our group is greater than that in the earlier report by Blomquist.
1 Whether this reflects a difference in endemic strains based on location or an ever-widening resistance profile over time is uncertain.
Our study is limited in its scope and ability to determine whether the presence of MSSA and MRSA on inanimate clinic surfaces is a legitimate threat to patients. It does, however, indicate that office-cleaning protocols are at least keeping these pathogens from becoming endemic to the outpatient environment. It also suggests a constant reintroduction of S. aureus clones to the clinic, increasing the chances of nosocomial infection if cleaning protocols are relaxed. Additionally, it may offer clinical guidance to ophthalmologists presented with patients who have ocular or periocular infections, given the range of antibiotic resistance found in our study. Clinicians may want to consider performing culture and susceptibility testing sooner rather than later or changing their initial prescriptions for empiric or prophylactic antimicrobial therapy. It is interesting that a recent prospective study 30 of conjunctival bacterial isolates in patients undergoing cataract surgery showed that susceptibility of ocular surface flora was greatest for gentamicin (eg, susceptibility for coagulase-negative staphylococci was 95% for gentamicin vs 64.5% for ciprofloxacin).
In any case, antibiotic resistance in S. aureus appears to be an ever-increasing concern that demands further exploration. Our study provides valuable insight into the prevalence of a common pathogen in the ophthalmology clinic. The screening protocol herein could help to identify potential hotspots for pathogen transmission and infection to patients and staff. Staff education and cleaning protocols can be directed and modified based on a regular surveillance program such as the one described in this study, and patients could benefit from the increased attention to preventing the spread of pathogens via commonly touched clinic surfaces.
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